HUM Humana

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Integrated health insurance services primarily delivering Medicare Advantage and Medicaid plans with complementary healthcare services via CenterWell
• • New emphasis on Medicare Advantage individual plans covering 5.2 million members, including approx. 1.0 million in Florida generating $17.8B premiums (20% of individual MA revenue)
• • Strategic focus on transitioning providers from fee-for-service to value-based care, enhancing integrated care and member engagement through data analytics
• • Medicare Advantage premiums and services revenue $106.3B, comprising 82.6% of segment total; 83% of total revenue derived from federal contracts, CMS-partnered
• • Noteworthy: Renewed all Medicare Advantage contracts for 2026, including expanded Florida presence accounting for 14% of consolidated premiums and services revenue

Management Discussion & Analysis

• • Revenue $129.7B, up 10.1% YoY; premiums $122.8B (+9.6%), services $5.8B (+31.6%), investment income down 17.9% to $1.0B
• • Net income $1.2B, flat YoY (-0.9%); operating margin 2.1% (operating income $2.7B on $129.7B revenue) vs 2.2% in 2024
• • Best performing segment: Insurance income from operations $1.7B, up 29.1% on premiums $122.8B; worst: CenterWell flat at $1.3B income despite 12.7% revenue growth
• • Benefit ratio 90.2% vs 89.8%; Operating cost ratio increased to 12.0% from 11.8% driven by CenterWell segment; Insurance cost ratio fell slightly to 9.1%
• • Value creation charges $449M in 2025; impairments $253M; capital spending reduced (depreciation down 16.8% to $698M)
• • Cash flow: No specific CAPEX, dividend, or buyback $ disclosed; operating cash flow seasonally impacted by Medicare design changes
• • 2026 outlook: Anticipate Medicare Advantage membership growth (~25% individual, 150k group), PDP growth ~1M; risks from regulatory changes and pricing pressures noted

Risk Factors

• • CMS 2025 Medicare Advantage Star Ratings declined, risking lower 2026 quality bonus payments and revenues due to pending lawsuit outcome
• • Exposure to geopolitical climate risk from frequent/intense catastrophes including pandemics and hurricanes affecting medical cost trends
• • Dependency on third-party IT providers for critical data services risks service disruptions and contract adversities
• • Competitive pressure from larger insurers and emerging entrants intensifies premium price containment challenges
• • Lawsuit exposure under False Claims Act for Medicare risk-adjustment practices with potential for treble damages and insurance coverage gaps

What are the latest HUM SEC filings in 2026?

Humana (HUM) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on April 29, 2026, an 8-K current report on July 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did HUM file its most recent 10-K annual report?

Humana (HUM) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view HUM 10-Q quarterly reports?

Humana (HUM)'s most recent 10-Q quarterly report was filed on April 29, 2026. SignalX displays every HUM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has HUM filed recently?

Humana (HUM)'s most recent 8-K was filed on July 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find HUM insider trading activity (Form 4)?

SignalX aggregates every HUM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does HUM file with the SEC?

Humana (HUM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HUM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Humana (HUM).

What is HUM's SEC CIK number?

Humana (HUM)'s SEC CIK (Central Index Key) number is 49071. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 49071 to look up all HUM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find HUM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Humana (HUM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.